Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LeMaitre Vascular, Inc. reported insider equity transactions by its president and director dated 12/11/2025 and 12/12/2025. The reporting person acquired small amounts of common stock at $0 per share through the release of dividend equivalent rights tied to earlier restricted and performance stock unit awards. On those same dates, the issuer withheld 297 and 302 shares on multiple transactions to cover tax withholding obligations triggered by the vesting of awards granted on 12/11/2021 and 12/12/2022. After all reported activity, the insider directly owned 22,251 shares of LeMaitre Vascular common stock.
LeMaitre Vascular Inc disclosed insider equity transactions by its Senior V. P., Operations in December 2025. The officer acquired small amounts of common stock through the release of dividend equivalent rights on 12/11/2025 and 12/12/2025, with each right economically equivalent to one share of common stock.
On those dates, the issuer also withheld 90 shares on three separate occasions to satisfy tax withholding obligations tied to the vesting of restricted stock units and performance stock units originally granted in 2021 and 2022. After these transactions, the officer beneficially owned 4,417 shares of common stock directly.
LeMaitre Vascular, Inc. director filed a report of routine equity-related transactions. On 12/11/2025 and 12/12/2025, the director acquired 25, 18, and 18 shares of common stock at a price of $0 per share following the release of dividend equivalent rights tied to prior stock awards. After these transactions, the director directly beneficially owned 10,183 shares of common stock.
The filing shows dividend equivalent rights converting into common stock on a one-for-one basis, connected to restricted stock unit and performance stock unit awards granted in 2021 and 2022. Fractional shares from these rights, if any, were settled in cash, leaving derivative right balances such as 19.974 and 19.291 units outstanding.
LeMaitre Vascular, Inc. disclosed that a director acquired common stock through the vesting of equity-based awards on 12/12/2025. Two transactions converted derivative awards into common stock, each for 5 shares of common stock at a price of $0 per share under transaction code "M," which typically reflects the exercise or conversion of derivative securities.
The new shares came from the release of dividend equivalent rights that were tied to restricted stock unit and performance stock unit awards originally granted on 12/12/2022. Each dividend equivalent right was the economic equivalent of one share of LeMaitre Vascular common stock, and any fractional shares were settled in cash, leaving no remaining dividend equivalent rights outstanding after these vesting events.
A LeMaitre Vascular director reported automatic share acquisitions tied to existing equity awards. On 12/12/2025, dividend equivalent rights linked to stock awards converted into common shares at an exercise price of $0, with the transactions coded as exercises (code M). The director received 5 shares from dividend equivalent rights associated with a restricted stock unit award granted on 12/12/2022 and another 5 shares from rights linked to a performance stock unit award granted on the same date. Fractional shares from these rights, if any, were settled in cash, leaving a remaining balance of 0 dividend equivalent rights.
A LeMaitre Vascular Inc. director reported stock transactions tied to dividend equivalent rights that vested on 12/12/2025. The director acquired 5 shares of common stock in each of two transactions at a price of $0 per share, reflecting the release of dividend equivalent rights on a one-for-one basis into common stock.
Following these transactions, the director beneficially owned 62,350 shares of LeMaitre Vascular common stock directly. The derivative positions shown were dividend equivalent rights linked to restricted stock unit and performance stock unit awards granted on 12/12/2022, each right being the economic equivalent of one share. After vesting, the number of these derivative rights was reduced to zero, with any fractional shares settled in cash.
LeMaitre Vascular reported a director receiving additional common shares through equity awards. On 12/12/2025, the director acquired 5 shares of common stock in each of two transactions at a stated price of $0 per share, reflecting the release of dividend equivalent rights tied to earlier stock awards. After these transactions, reported beneficial ownership entries were 5,317 and 5,322 common shares held directly. Related dividend equivalent right positions were reduced to zero, with any fractional shares settled in cash at vesting.
LeMaitre Vascular Inc. reported that one of its directors acquired common stock through the release of dividend equivalent rights on 12/12/2025. Two transactions each delivered 5 shares of common stock at an exercise price of $ 0 per share, following the vesting of restricted stock unit and performance stock unit awards originally granted on 12/12/2022.
Each dividend equivalent right is the economic equivalent of one share of common stock, and any fractional shares were settled in cash, resulting in a final balance of zero dividend equivalent rights. After these transactions, the director reported direct holdings of 3,460 and 3,465 common shares, plus 181 shares held indirectly through a spouse.
LeMaitre Vascular reported an equity grant to its Senior Vice President of Operations. On 12/10/2025, the executive received 1,177 shares of common stock as a restricted stock unit award at a stated price of $0, bringing direct beneficial ownership of common stock to 4,660 shares.
The executive also received a stock option covering 7,222 shares of common stock at an exercise price of $83.66 per share, expiring on 12/10/2032. The restricted stock units vest 25% on 12/1/2026, with the remainder vesting in equal annual installments over the following three years, and the issuer may withhold shares to satisfy tax obligations. The option vests over four years, with 25% vesting on the first anniversary of the grant date and the balance in equal annual installments over the next three years.
LeMaitre Vascular Inc's chief financial officer reported receiving new equity awards in the company’s stock. On 12/10/2025, the officer acquired 1,177 shares of common stock at a stated price of $0, bringing direct ownership to 2,398 common shares.
The filing also shows a new stock option grant for 7,222 shares with an exercise price of $83.66 and an expiration date of 12/10/2032. The 1,177-share award is structured as restricted stock units that vest 25% on 12/1/2026, with the rest vesting in equal annual installments over the following three years. The option vests over four years at 25% on the first anniversary of the grant date listed, with the balance vesting in equal annual installments over the next three years.